Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer

Li, Zhengyan; Wang, Jintao; Chen, Gang; Shan, Zhi‐Guo; Wang, Tingting; Shen, Yang; Yan, Zong‐Bao; Li, Peng; Mao, Fang‐Yuan; Teng, Yong‐Sheng; Liu, Jinshan; Zhou, Yuanyuan; Zhao, Yongliang; Zhuang, Yuan

doi:10.1016/j.clim.2021.108753

Cited by 14 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human gastric cancer, it was found that tumor-derived GM-CSF induces the proliferation of neutrophils and stimulates B7-H3 expression in neutrophils via the JAK2-STAT3 signaling pathway. B7-H3-high neutrophils, which are often found in the gastric cancer TME, are correlated with a poor prognosis and tumor progression in human gastric cancer [ 94 ]. DCs were also found to be correlated with B7-H3.…”

Section: B7-h3 In the Tumor Microenvironmentmentioning

confidence: 99%

“…In contrast, in stomach cancer cell lines and xenograft models, it was revealed that B7-H3 knockdown significantly inhibited cancer invasion and metastasis capacity [ 150 ]. Mechanistically, B7-H3 + neutrophils have been found in gastric cancer tissues, which increases tumor progression and is a negative predictive marker of reduced survival [ 94 ], and a more restricted CD8 + T cell location was noted in B7-H3-high gastric cancer samples, indicating a potential immunosuppressive role of B7-H3 in gastric cancer, although no significant survival difference was observed between the B7-H3-high and B7-H3-low groups in the study [ 151 ]. Evidence for the role of B7-H3 in gastric cancer is limited and conflicting, and more studies, particularly in patients with gastric cancer, are warranted.…”

Section: B7-h3 In Different Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Zhao

Xia

et al. 2022

J Hematol Oncol

View full text Add to dashboard Cite

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients.

show abstract

Section: B7-h3 In the Tumor Microenvironmentmentioning

confidence: 99%

Section: B7-h3 In Different Malignanciesmentioning

confidence: 99%

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Zhao

Xia

et al. 2022

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…CD276 (B7-H3, B7 homolog 3) belongs to the B7 family of cell-surface receptors [ 294 ], and is expressed by activated DCs [ 295 , 296 ] and PMNs [ 297 ], but also various non-immune cell types [ 298 , 299 , 300 ] and tumors [ 301 ]. Binding to its receptor TLT-2 (triggering receptor expressed on myeloid cells-like transcript 2) [ 302 , 303 ], apparent on myeloid cells and B cells [ 304 , 305 ] as well as T-cell populations [ 302 ], yielded different results, either inhibiting [ 306 , 307 ] or enhancing [ 295 , 302 , 303 , 308 ] T-cell activity.…”

Section: Emerging Immune Checkpoints and Their Impact On Non-t-cell I...mentioning

confidence: 99%

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Kuske

Haist

Jung

et al. 2022

Cancers

View full text Add to dashboard Cite

The approval of immune checkpoint inhibitors (ICI) that serve to enhance effector T-cell anti-tumor responses has strongly improved success rates in the treatment of metastatic melanoma and other tumor types. The currently approved ICI constitute monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein (CTLA)-4 and anti-programmed cell death (PD)-1. By this, the T-cell-inhibitory CTLA-4/CD80/86 and PD-1/PD-1L/2L signaling axes are inhibited. This leads to sustained effector T-cell activity and circumvents the immune evasion of tumor cells, which frequently upregulate PD-L1 expression and modulate immune checkpoint molecule expression on leukocytes. As a result, profound clinical responses are observed in 40–60% of metastatic melanoma patients. Despite the pivotal role of T effector cells for triggering anti-tumor immunity, mounting evidence indicates that ICI efficacy may also be attributable to other cell types than T effector cells. In particular, emerging research has shown that ICI also impacts innate immune cells, such as myeloid cells, natural killer cells and innate lymphoid cells, which may amplify tumoricidal functions beyond triggering T effector cells, and thus improves clinical efficacy. Effects of ICI on non-T cells may additionally explain, in part, the character and extent of adverse effects associated with treatment. Deeper knowledge of these effects is required to further develop ICI treatment in terms of responsiveness of patients to treatment, to overcome resistance to ICI and to alleviate adverse effects. In this review we give an overview into the currently known immunomodulatory effects of ICI treatment in immune cell types other than the T cell compartment.

show abstract

“…Neutrophils are abundant in peripheral blood and solid tumors, including in GC. Enriched neutrophils were significantly associated with larger tumor size, advanced TNM stage, and poor survival for patients with GC[ 17 , 18 ]. GC cells and the TME can exert multiple regulatory roles to remodel neutrophils and promote cancer development.…”

Section: Mechanisms Of Immune Evasion In Gcmentioning

confidence: 99%

Immune evasion mechanisms and therapeutic strategies in gastric cancer

Ma¹,

Wang²,

Zhu³

et al. 2022

WJGO

View full text Add to dashboard Cite

Gastric cancer (GC) is a malignancy with a high incidence and mortality. The tumor immune microenvironment plays an important role in promoting cancer development and supports GC progression. Accumulating evidence shows that GC cells can exert versatile mechanisms to remodel the tumor immune microenvironment and induce immune evasion. In this review, we systematically summarize the intricate crosstalk between GC cells and immune cells, including tumor-associated macrophages, neutrophils, myeloid-derived suppressor cells, natural killer cells, effector T cells, regulatory T cells, and B cells. We focus on how GC cells alter these immune cells to create an immunosuppressive microenvironment that protects GC cells from immune attack. We conclude by compiling the latest progression of immune checkpoint inhibitor-based immunotherapies, both alone and in combination with conventional therapies. Anti-cytotoxic T-lymphocyte-associated protein 4 and anti-programmed cell death protein 1/programmed death-ligand 1 therapy alone does not provide substantial clinical benefit for GC treatment. However, the combination of immune checkpoint inhibitors with chemotherapy or targeted therapy has promising survival advantages in refractory and advanced GC patients. This review provides a comprehensive understanding of the immune evasion mechanisms of GC, and highlights promising immunotherapeutic strategies.

show abstract

Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer

Cited by 14 publications

References 43 publications

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Immune evasion mechanisms and therapeutic strategies in gastric cancer

Contact Info

Product

Resources

About